List of Excipients in Branded Drug PIOGLITAZONE AND METFORMIN HYDROCHLORIDE

Generic Drugs Containing PIOGLITAZONE AND METFORMIN HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Macleods Pharmaceuticals Limited	pioglitazone and metformin hydrochloride	33342-176	CELLULOSE, MICROCRYSTALLINE
Macleods Pharmaceuticals Limited	pioglitazone and metformin hydrochloride	33342-176	CROSCARMELLOSE SODIUM
Macleods Pharmaceuticals Limited	pioglitazone and metformin hydrochloride	33342-176	HYPROMELLOSES
Macleods Pharmaceuticals Limited	pioglitazone and metformin hydrochloride	33342-176	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PIOGLITAZONE AND METFORMIN HYDROCHLORIDE?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
2	HYPROMELLOSE
1	HYPROMELLOSES

Pioglitazone and Metformin Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Pioglitazone/metformin hydrochloride is a mature fixed-dose combination with limited composition-of-matter exclusivity but continuing opportunities in formulation, manufacturing efficiency, dose flexibility, and patient adherence. The strongest commercial concepts are immediate-release and extended-release tablets with improved swallowability, reduced gastrointestinal burden, lower tablet counts, and robust stability in high-dose metformin presentations.

What is the market and regulatory status of pioglitazone/metformin hydrochloride?

Pioglitazone/metformin hydrochloride combines a thiazolidinedione insulin sensitizer with a biguanide antihyperglycemic agent. In the United States, the reference products are Actoplus Met immediate-release tablets and Actoplus Met XR extended-release tablets, originally marketed by Takeda.

Attribute	Pioglitazone/metformin hydrochloride
Therapeutic class	Oral antihyperglycemic
Active ingredients	Pioglitazone hydrochloride equivalent and metformin hydrochloride
Indication	Type 2 diabetes mellitus, as an adjunct to diet and exercise
Immediate-release strengths	15 mg/500 mg; 15 mg/850 mg
Extended-release strengths	5 mg/1,000 mg; 10 mg/1,000 mg; 15 mg/1,000 mg
Common dosage form	Film-coated tablet
Regulatory pathway	Abbreviated New Drug Application for generics; possible 505(b)(2) pathway for materially differentiated products
Biosimilar relevance	None; this is a chemically synthesized small-molecule combination
Key safety constraints	Pioglitazone boxed warning for congestive heart failure; metformin risk of lactic acidosis; renal-function restrictions

The fixed-dose combination is intended for patients who require both agents and may reduce pill burden compared with separate pioglitazone and metformin tablets. FDA labeling requires attention to renal function, hepatic status, heart failure risk, hypoxia, contrast imaging procedures, and other factors affecting metformin safety.[1,2]

The commercial market is largely generic. A sponsor therefore needs either a cost advantage, a differentiated dosage form, a channel advantage, or intellectual-property protection around formulation or manufacturing.

What excipients are used in pioglitazone/metformin tablets?

The exact excipient profile depends on the manufacturer and dosage form. Reference labeling identifies conventional tablet excipients, while generic labels may use different materials if the product meets quality, bioequivalence, and regulatory requirements.

Immediate-release excipient architecture

Immediate-release tablets generally require:

• A high-load diluent for metformin hydrochloride
• A separate diluent or filler for pioglitazone hydrochloride
• A binder to support granule or tablet strength
• A disintegrant to promote rapid tablet breakup
• A lubricant and, in some designs, a glidant
• A film-coating system for identification, protection, and swallowability

Metformin hydrochloride is highly water-soluble but is used at a relatively high dose. It can produce large, dense tablets with poor manufacturability if the formulation is not engineered carefully. Typical formulation approaches use wet granulation, dry granulation, or direct compression depending on powder flow, compressibility, and segregation behavior.

Potential excipient classes include:

Function	Candidate excipient classes	Development issue
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch-based fillers	Must support tablet size, hardness, and dissolution
Binder	Povidone, copovidone, hydroxypropyl cellulose, pregelatinized starch	Excess binder can delay disintegration
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Must overcome high tablet density
Glidant	Colloidal silicon dioxide	Controls flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Over-lubrication can slow dissolution
Film former	Hypromellose, polyvinyl alcohol, methacrylate polymers	Supports identification and moisture control
Plasticizer	Polyethylene glycol, triethyl citrate	Improves coating flexibility
Opacifier/colorant	Titanium dioxide or permitted color systems	Subject to jurisdiction-specific requirements

A key development concern is content uniformity of the low-dose pioglitazone component within a formulation dominated by metformin. Particle-size engineering, ordered mixing, granulation, or separate granulation of the two actives can reduce segregation risk.

Extended-release excipient architecture

Extended-release products require a release-controlling matrix or membrane system. Common approaches include:

• Hydrophilic polymer matrices based on hypromellose
• Hydrophobic matrix systems using ethylcellulose or lipid excipients
• Multiparticulate systems with coated granules or pellets
• Bilayer or multilayer tablets
• Osmotic systems, although these are more complex and less likely to be cost-optimal for this product

The 1,000 mg metformin load creates a large formulation challenge. A matrix tablet must maintain release performance across the gastrointestinal tract without excessive tablet size, dose dumping, or sensitivity to food.

Hydrophilic matrix systems are usually the most commercially practical. Polymer viscosity grade, polymer concentration, granule density, compression force, and tablet geometry materially affect release. The formulation should be evaluated under discriminatory dissolution conditions, including pH changes, agitation rates, alcohol exposure where relevant, and fed and fasted conditions.

What formulation patents protect pioglitazone/metformin products?

The original active ingredients and early combination products are mature technologies. Commercial protection is therefore more likely to arise from formulation, release profile, manufacturing process, or device-related claims than from broad active-ingredient claims.

Potentially protectable subject matter includes:

1. A specific extended-release matrix composition.
2. A bilayer tablet separating immediate-release pioglitazone from extended-release metformin.
3. A multiparticulate metformin system with controlled release.
4. A low-segregation manufacturing process for combining a low-dose pioglitazone component with high-dose metformin.
5. A coating system that improves moisture stability or swallowability.
6. A tablet geometry that reduces size while preserving dissolution performance.
7. A formulation that maintains bioequivalence under fed and fasted conditions.
8. A process that reduces degradation, sticking, capping, or weight variation.
9. A modified-release product with a defined pharmacokinetic profile.
10. A combination dosage form that reduces gastrointestinal exposure peaks.

Broad excipient claims are difficult to enforce when they recite standard materials such as hypromellose, microcrystalline cellulose, or magnesium stearate. Stronger claims usually require a defined composition range, release profile, process parameter, or measurable product attribute.

When does pioglitazone/metformin lose exclusivity?

The principal small-molecule exclusivity barriers have largely expired. Pioglitazone and metformin are long-established generic active ingredients, and FDA-approved generic versions of combination tablets compete on price and distribution.

Exclusivity category	Status
Pioglitazone composition of matter	Expired
Metformin composition of matter	Expired
Original immediate-release combination exclusivity	Expired
Original extended-release combination exclusivity	Largely expired
Pediatric exclusivity	Historical and expired
Regulatory exclusivity for new indication	Not a current market barrier for the established combination
Biosimilar exclusivity	Not applicable

The relevant question is no longer when the active ingredients lose exclusivity. It is whether a proposed product can obtain protection for a differentiated formulation or whether an ANDA can enter without infringing listed patents.

What is the Orange Book status of pioglitazone/metformin?

The FDA Orange Book identifies approved products, therapeutic-equivalence evaluations, patent information, and exclusivity data for approved drug products.[3] For a generic sponsor, the critical review involves:

• Reference listed drug designation
• Therapeutic-equivalence rating
• Listed patents for the relevant strength and dosage form
• Expired or delisted patent entries
• Certification requirements under Paragraph I, II, III, or IV
• Whether the product is immediate-release or extended-release
• Whether the ANDA must address a method-of-use patent

The existence of an Orange Book patent listing does not establish that the patent will survive litigation. Conversely, an unlisted formulation concept may still create non-Orange-Book risk if the sponsor commercializes a product covered by process, packaging, or non-listed intellectual property.

A product-specific Orange Book review should be performed against the current FDA database before filing. Patent status can change through expiration, disclaimer, litigation, delisting, or regulatory listing updates.

Which companies are challenging pioglitazone/metformin patents?

The product is commercially mature, and generic competition has already entered the U.S. market. Challenges have generally been associated with ANDA filings directed to immediate-release or extended-release combination products rather than with new chemical entities.

For a current competitive review, the relevant companies include:

• Established generic manufacturers with diabetes portfolios
• Vertical manufacturers producing metformin and pioglitazone separately
• Contract development and manufacturing organizations with high-dose tablet capability
• Regional pharmaceutical companies in markets where fixed-dose combinations remain underpenetrated

The most relevant competitive distinction is not the identity of the active ingredients. It is manufacturing scale, tablet size, dissolution robustness, supply reliability, and payer access.

What generic entry risks exist for pioglitazone/metformin?

Generic entry risk is high for conventional immediate-release tablets and moderate for technically differentiated extended-release products.

Immediate-release risk

Immediate-release products have:

• Mature active ingredients
• Conventional excipient systems
• Established bioequivalence methods
• Low formulation complexity
• Multiple potential manufacturers

A new immediate-release product is likely to face rapid price competition unless it has a clear cost or distribution advantage.

Extended-release risk

Extended-release products retain more formulation complexity because the sponsor must demonstrate:

• Consistent release across dose strengths
• Acceptable pharmacokinetics
• Robustness to food effects
• Control of dose dumping
• Batch-to-batch polymer performance
• Manufacturability at a 1,000 mg metformin load

Extended-release products can support better margins, but development failure risk is higher. A technically weak matrix may pass initial dissolution testing while failing under altered agitation, pH, or food conditions.

How strong is the patent estate for pioglitazone/metformin?

The legacy patent estate is weak as a barrier to conventional generic entry. The strongest new protection would be a narrowly drafted formulation or process patent supported by comparative data.

Patent subject	Likely commercial strength
Broad combination of pioglitazone and metformin	Low
Conventional immediate-release tablet	Low
Standard film coating	Low
Defined extended-release matrix with performance limits	Moderate
Novel bilayer or multiparticulate architecture	Moderate to high, depending on claims
Manufacturing process reducing segregation or improving yield	Moderate
Specific dissolution and pharmacokinetic profile	Moderate, but enforcement can be fact-intensive
New indication or safety-related use	Limited for routine generic strategy

Patent strength depends on claim breadth, enablement, freedom-to-operate, prior art, prosecution history, and the ability to detect infringement through product testing. Formulation patents that rely only on broad excipient categories are vulnerable to design-around.

What excipient strategies create commercial opportunities?

1. Smaller or easier-to-swallow tablets

Metformin drives tablet size. A formulation that reduces tablet dimensions without compromising dose uniformity or dissolution could improve adherence and create a differentiated product.

Potential approaches include high-compressibility excipients, optimized granulation, higher drug loading, multilayer compression, and controlled particle-size distribution.

The commercial value is strongest in patients taking multiple oral diabetes medicines.

2. Improved gastrointestinal tolerability

Metformin commonly causes gastrointestinal adverse effects. Excipients cannot eliminate the active ingredient’s tolerability profile, but a controlled-release formulation can reduce peak exposure and improve administration convenience.

A sponsor should generate comparative data on:

• Nausea
• Diarrhea
• Abdominal discomfort
• Treatment discontinuation
• Food-related tolerability
• Pharmacokinetic exposure

A tolerability claim requires clinical evidence. An excipient change alone does not establish a superior safety profile.

3. Robust extended-release systems

The extended-release segment offers the clearest technical opportunity. A well-designed matrix can combine:

• Once-daily administration
• Reduced peak-related gastrointestinal effects
• Lower pill burden
• Consistent release across strengths
• Manufacturing scalability

The formulation should avoid excessive polymer loading, which increases tablet size and may create incomplete release or variability.

4. Bilayer tablets

A bilayer platform can separate pioglitazone from metformin and allow independent optimization of each active ingredient. It may also reduce segregation and permit different release rates.

The disadvantages are higher equipment cost, more complex process controls, and increased risk of layer adhesion, cross-contamination, weight variation, and delamination.

5. Multiparticulate delivery

Coated granules or pellets can improve release control and dose flexibility. Multiparticulates may also provide a path to sprinkle or alternative administration formats, subject to labeling and bioequivalence requirements.

The economics are less favorable than a conventional tablet unless the formulation delivers a clear benefit such as dose flexibility, improved swallowing, or a differentiated pharmacokinetic profile.

6. Excipient substitution and supply-chain resilience

Excipients with multiple qualified suppliers can reduce manufacturing interruption risk. A sponsor should avoid unnecessary dependence on a single grade or supplier for:

• High-viscosity hypromellose
• Crospovidone
• Colloidal silicon dioxide
• Film-coating systems
• Specialized direct-compression diluents

Supplier changes can affect dissolution, hardness, friability, and stability. A formulation designed around broad material specifications rather than a single proprietary grade is more resilient.

How does pioglitazone/metformin compare with competing diabetes combinations?

Combination	Main advantage	Main formulation opportunity	Principal commercial constraint
Pioglitazone/metformin	Low-cost insulin sensitization and established use	Smaller tablet, XR matrix, cost-efficient FDC	Pioglitazone safety concerns and generic pricing
Sitagliptin/metformin	Established DPP-4 combination	XR delivery and dose flexibility	Stronger competition and branded franchise history
Empagliflozin/metformin	Cardiovascular and renal outcome positioning	XR and once-daily delivery	Higher cost and SGLT2-related safety considerations
Dapagliflozin/metformin	Once-daily combination potential	Modified-release metformin	Brand and generic timing varies by market
Glimepiride/metformin	Low-cost combination	Immediate-release size and tolerability	Hypoglycemia risk
Rosiglitazone/metformin	Mechanistically similar	Limited opportunity	Restricted commercial demand and safety history

Pioglitazone/metformin is most competitive where treatment cost and access outweigh newer-agent outcome advantages. It is less competitive in premium markets dominated by GLP-1, GIP/GLP-1, and SGLT2 therapies.

What FDA regulatory pathway applies to a new product?

A conventional generic tablet would normally use an ANDA and must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference product.[4] The formulation can use different inactive ingredients if the product meets applicable safety, quality, and performance requirements.

A materially differentiated product may require a 505(b)(2) application when the sponsor relies partly on FDA findings for an approved product but introduces a new dosage form, route, formulation, or clinical feature. The pathway depends on the extent of reliance and the nature of the change.

Important regulatory workstreams include:

• Comparative dissolution
• Bioequivalence under fed and fasted conditions
• In vitro alcohol dose-dumping assessment where relevant
• Stability under ICH conditions
• Extractables and leachables for specialized coatings or packaging
• Impurity and degradation-product control
• Nitrosamine risk assessment
• Excipient safety qualification
• Manufacturing-process validation
• Container-closure compatibility

FDA’s guidance on oral modified-release dosage forms is particularly relevant to extended-release development.[5]

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are more important than active-ingredient patent barriers. The main technical risks are:

• Poor flow of high-dose metformin blends
• Segregation of low-dose pioglitazone
• Tablet sticking and picking
• Inadequate tensile strength
• Excessive tablet size
• Variable polymer hydration
• Dissolution drift after scale-up
• Coating defects
• Food-effect variability
• Stability changes caused by moisture uptake

A commercial formulation should be designed for high-speed compression, conventional coating equipment, and dual-source excipient procurement. Process patents may have value when they protect a measurable manufacturing advantage, such as reduced blend segregation or improved yield.

What licensing deals are available?

No major current licensing transaction is required to commercialize a standard pioglitazone/metformin generic. The most relevant deal structures are:

• Licensing an extended-release platform
• Acquiring a ready-to-file ANDA
• Contract development with an option to purchase technology
• Regional licensing for markets with limited generic competition
• Co-development with a diabetes-focused manufacturer
• In-licensing a bilayer, multiparticulate, or sprinkle formulation

A platform license is commercially justified only if it produces a demonstrable advantage in tablet size, dissolution robustness, dose flexibility, or clinical tolerability. A standard hypromellose matrix usually does not justify substantial royalty burden unless supported by enforceable claims and comparative data.

What is the revenue exposure and launch opportunity?

Revenue potential is constrained by generic pricing in the United States but can be attractive in selected international markets. The strongest opportunities are:

1. A low-cost, reliable immediate-release product for tender and public-sector channels.
2. An extended-release product with once-daily positioning.
3. A smaller tablet for adherence-sensitive patients.
4. A regional product in markets where fixed-dose combinations remain underdeveloped.
5. A dual-source manufacturing platform that reduces supply interruptions.
6. A line extension with multiple dose ratios.

The main downside is declining price after multiple generic entrants. A sponsor should model launch economics using at least three scenarios:

Scenario	Product profile	Expected commercial position
Commodity generic	Conventional immediate-release tablet	Low margin, volume dependent
Differentiated generic	Optimized tablet size or robust XR profile	Moderate margin, regulatory execution dependent
Specialty line extension	Bilayer, multiparticulate, or adherence-focused product	Higher potential margin, higher development and litigation risk

Key Takeaways

• Pioglitazone/metformin is a mature small-molecule combination with little remaining active-ingredient exclusivity.
• Immediate-release products are technically accessible but exposed to rapid generic price erosion.
• Extended-release metformin is the strongest formulation opportunity.
• The most valuable excipient strategies target tablet size, release control, manufacturability, and gastrointestinal tolerability.
• Bilayer and multiparticulate products may support stronger differentiation but carry higher manufacturing costs.
• Patent value is more likely to come from defined formulation performance or manufacturing processes than from broad excipient claims.
• No biosimilar pathway applies because both ingredients are chemically synthesized small molecules.
• FDA approval will generally proceed through an ANDA for a conventional generic or a 505(b)(2) application for a materially differentiated product.
• Commercial success depends on production cost, supply reliability, tablet burden, and market-specific reimbursement rather than on legacy exclusivity.

FAQs About Pioglitazone and Metformin Excipient Development

Can metformin and pioglitazone be formulated in one immediate-release tablet?

Yes. The primary challenges are high metformin loading, low-dose pioglitazone uniformity, tablet size, and dissolution control.

Which excipient is best for extended-release metformin?

Hypromellose is a common starting point for hydrophilic matrix development, but the optimal grade and concentration depend on tablet dimensions, compression conditions, dissolution targets, and pharmacokinetic requirements.

Can an excipient change support a new patent?

Yes, but a patent is more defensible when it claims a specific composition, process, release profile, or measurable performance advantage rather than a routine substitution of one standard excipient for another.

Is a pioglitazone/metformin product eligible for biosimilar approval?

No. Biosimilar approval applies to biological products. Pioglitazone and metformin hydrochloride are chemically synthesized active ingredients.

What is the most attractive commercial dosage form?

An extended-release, once-daily tablet with reduced size, stable dissolution, and evidence of improved gastrointestinal tolerability offers the strongest differentiation relative to a conventional immediate-release generic.

References

1. U.S. Food and Drug Administration. (2023). Actoplus Met prescribing information.
2. U.S. Food and Drug Administration. (2023). Actoplus Met XR prescribing information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format.
5. U.S. Food and Drug Administration. (1997). SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes. Guidance for industry.